Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.65 |
| ▸ | NOS1 | P29475 | 2/20 | 0.65 |
| ▸ | NOS2 | P35228 | 2/20 | 0.65 |
| ▸ | GABRP | O00591 | 5/20 | 0.56 |
| ▸ | GABRD | O14764 | 5/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.56 |
| ▸ | GABRE | P78334 | 5/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.56 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15018104 | 0.82 | GABRP (0.62) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL8322579 | 0.79 | NOS3 (1.00) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL7046428 | 0.77 | NOS3 (0.68) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL554353 | 0.75 | NOS3 (0.70) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL7049168 | 0.75 | NOS3 (0.59) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL27515768 | 0.74 | NOS3 (0.54) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL11325941 | 0.74 | NPSR1 (0.60) | AGBL2NPSR1ALOX15RXRARXRB | |
| SCHEMBL2728906 | 0.73 | CYP1A2 (0.42) | NOS3NOS1NOS2AGBL2NPSR1 | |
| SCHEMBL2728907 | 0.73 | CYP1A2 (0.42) | NOS3NOS1NOS2AGBL2NPSR1 | |
| SCHEMBL4005845 | 0.73 | CPB2 (0.55) | NOS3NOS1NOS2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2790511-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9206199-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
| EP-2790511-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2632464-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| WO-2013090271-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | NOS3 1097/4885NOS1 550/4885NOS2 922/4885 |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | NOS3 1075/4885NOS1 538/4885NOS2 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.